• Thaimattam Ram
• Banerjee Rahul
• Miglani Rajni
• Iqbal Javed

Current pharmaceutical design

• Publish Date: 2007
• ISSN: 1873-4286
• Volume: 13
• Issue: 27
• Pages: 2751-65
• Medium: Internet
• Language: English
• Citation (JAMA): Thaimattam Ram, Banerjee Rahul, Miglani Rajni, et al. Protein Kinase Inhibitors: Structural Insights into Selectivity.. Curr. Pharm. Des. 2007;13:2751-65

Abstract

Protein kinases are involved in many diseases like cancer, inflammation, cardiovascular disease, and diabetes. They have become attractive target classes for drug development, making kinase inhibitors as important class of therapeutics. The success of small-molecule ATP-competitive kinase inhibitors such as Gleevec, Iressa, and Tarceva has attracted much attention in the recent past. Kinases make use of ATP for phosphorylation of a specific residue(s) on their protein substrates. More than 400 X-ray structures of about 70 different kinases are publicly available. These structures provide insights into selectivity and mechanisms of inhibition. However, prediction of binding specificity of kinase inhibitors based on structural information alone appears to be insufficient. Here, we will review these observations to gain insights into the rules that govern protein kinase inhibitor selectivity.

This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.